Medis Pharmaceuticals Reports Clinical Trial Results of Enoxa for the Prevention of Postoperative Subclinical Thrombosis
Shots:
- The clinical trial evaluated the equivalence of Enoxa to Sanofi’s Lovenox in patients (n= 74 vs 71) with digestive cancers to prevent postoperative subclinical thrombosis across Tunisia
- The 1EP of the study was asymptomatic thromboembolic events assessed by Doppler ultrasound & 2EPs include thrombotic events, heparin-induced thrombocytopenia, bleeding events, and deaths
- As per the results, out of the evaluable patients, 4.1% vs 5.6% depicted a subclinical venous thrombosis whereas 6.9% vs 8.6% of patients showed combined clinical & subclinical events. Moreover, in terms of other 2EPs, there were no significant differences between the groups & death occurred in 12.6% vs 7.4% of patients
Ref: Center For Biosimilar | Image: Anthos Therapeutics
Related News:- Anthos’ Abelacimab Receives the US FDA’s Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
